Univariate analysis of outcome
| . | Preimatinib cohort (N = 266) . | Imatinib cohort . | Preimatinib vs any imatinib . | Late vs early imatinib . | Pre- vs late vs early imatinib (trend) . | ||
|---|---|---|---|---|---|---|---|
| Any imatinib (N = 175) . | Late imatinib (N = 86) . | Early imatinib (N = 89) . | |||||
| Percent at 4 y (95% CI) . | |||||||
| OS | 22 (17-27) | 38 (31-45) | 33 (23-43) | 43 (32-53) | OR = 0.67 (0.53-0.83) P = .0003 | OR=0.75 (0.52-1.09) P = .1 | OR=0.77 (0.67-0.88) P < .0001 |
| EFS | 18 (13-22) | 33 (26-40) | 28 (18-37) | 37 (27-48) | OR = 0.65 (0.52-0.80) P = .0001 | OR=0.74 (0.51-1.06) P = .1 | OR=0.75 (0.66-0.85) P < .0001 |
| RFS | 33 (26-41) | 50 (41-58) | 46 (33-58) | 53 (41-66) | OR = 0.59 (0.46-0.79) P = .0003 | OR=0.67 (0.42-1.09) P = .1 | OR=0.72 (0.61-0.85) P = .0001 |
| Survival free from death in remission | 64 (55-73) | 72 (64-80) | 66 (53-80) | 76 (66-86) | OR = 0.81 (0.53-1.24) P = .3 | OR=0.79 (0.41-1.52) P = .5 | OR=0.86 (0.67-1.11) P = .2 |
| . | Preimatinib cohort (N = 266) . | Imatinib cohort . | Preimatinib vs any imatinib . | Late vs early imatinib . | Pre- vs late vs early imatinib (trend) . | ||
|---|---|---|---|---|---|---|---|
| Any imatinib (N = 175) . | Late imatinib (N = 86) . | Early imatinib (N = 89) . | |||||
| Percent at 4 y (95% CI) . | |||||||
| OS | 22 (17-27) | 38 (31-45) | 33 (23-43) | 43 (32-53) | OR = 0.67 (0.53-0.83) P = .0003 | OR=0.75 (0.52-1.09) P = .1 | OR=0.77 (0.67-0.88) P < .0001 |
| EFS | 18 (13-22) | 33 (26-40) | 28 (18-37) | 37 (27-48) | OR = 0.65 (0.52-0.80) P = .0001 | OR=0.74 (0.51-1.06) P = .1 | OR=0.75 (0.66-0.85) P < .0001 |
| RFS | 33 (26-41) | 50 (41-58) | 46 (33-58) | 53 (41-66) | OR = 0.59 (0.46-0.79) P = .0003 | OR=0.67 (0.42-1.09) P = .1 | OR=0.72 (0.61-0.85) P = .0001 |
| Survival free from death in remission | 64 (55-73) | 72 (64-80) | 66 (53-80) | 76 (66-86) | OR = 0.81 (0.53-1.24) P = .3 | OR=0.79 (0.41-1.52) P = .5 | OR=0.86 (0.67-1.11) P = .2 |
Overall ratio (brackets denote 95% CI). OR <1 indicates better outcome in the later comparator(s) (ie, better outcome in the any imatinib compared with preimatinib cohort, better outcome in early imatinib compared with the late imatinib cohort, and better outcome in early imatinib compared with the late imatinib compared with the preimatinib cohort). P values that are significant between the cohorts are shown in bold.